This case adds favorable evidence to the pathogenic role of aβ2GPI IgA in arterial thrombosis, highlights the potential efficacy of antiplatelet therapy in non-criteria aPLs-associated APS, challenges the conventional anticoagulation-centered paradigm, and provides novel insights into individualized management for this subgroup. The gene discussed is CD79A; the disease is Arterial thrombosis.